Bioline Launches New JetSeq™ Clean Kit for Next-Generation Sequencing
CINCINNATI, Aug. 02, 2017 (GLOBE NEWSWIRE) — Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced the further expansion of the JetSeq™ portfolio today for Next-Generation Sequencing (NGS) library preparation. The new JetSeq Clean Kit is a clean-up system based on paramagnetic bead technology, designed for efficient purification of nucleic […]
Meridian Bioscience Reports Third Fiscal Quarter 2017 Operating Results, Including Non-Cash Goodwill Impairment Charge,Declares Regular Cash Dividend, and Reaffirms Fiscal 2017 Guidance Excluding the Effect of Goodwill Impairment Charge
GENERAL HIGHLIGHTS CINCINNATI, July 27, 2017 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ:VIVO) today: reported fiscal 2017 third quarter and first nine months net revenues of $50.1 and $151.1 million, respectively, a decrease of 1% and an increase of 1%, respectively, from the same periods of the prior fiscal year; reported third quarter operating income […]
Meridian Announces Wholly Foreign Owned Enterprise (WFOE) Office in Beijing, China
CINCINNATI, July 20, 2017 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced the opening of Meridian Bioscience Beijing, LLC, its wholly foreign owned enterprise (WFOE) in Beijing, China. Meridian opened a representative office (RO) in Beijing in 2015, and now this office has been transitioned to a WFOE to better serve its Chinese customers. […]
Meridian Bioscience Comments on Recent FDA Press Statement
CINCINNATI, July 13, 2017 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ:VIVO). Meridian Bioscience, Inc. is providing the following comments regarding the FDA press statement and website announcement concerning the posting of the Form FDA-483 issued following the inspection of Magellan Diagnostics, which closed on June 29, 2017. As FDA noted, this Form represents the investigators’ observations […]
Meridian Bioscience Comments on Recent FDA Matters Related to Magellan Diagnostics
CINCINNATI, June 30, 2017 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ:VIVO). Meridian Bioscience, Inc. is providing the following clarifying comments regarding a June 29, 2017 letter from a group of U.S. Senators to the U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). The letter requested information on an […]
Meridian Bioscience, Inc. Expects to Report Third Quarter Fiscal 2017 Operating Results on Thursday, July 27, 2017
CINCINNATI, June 28, 2017 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading diagnostic and life science component company, expects to release its third quarter fiscal 2017 operating results before the NASDAQ market opens on Thursday, July 27, 2017. The release will be available shortly thereafter on Meridian’s website at www.meridianbioscience.com. About Meridian Bioscience, Inc. Meridian […]
Meridian Bioscience Comments on Recent FDA Posting Related to Magellan Diagnostics
CINCINNATI, June 06, 2017 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ:VIVO). Meridian Bioscience, Inc. is providing the following clarifying comments on the FDA’s recent recall notice posting. On May 17, 2017 Meridian Bioscience, Inc. commented that its subsidiary, Magellan Diagnostics, was working closely with the U.S. Food and Drug Administration (FDA) regarding the use of […]
Meridian Bioscience Comments on FDA Matter Involving its Subsidiary, Magellan Diagnostics
CINCINNATI, May 17, 2017 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ:VIVO). Meridian Bioscience, Inc.’s subsidiary, Magellan Diagnostics, Inc., is currently working with the U.S. Food and Drug Administration (FDA) regarding use of venous blood (blood drawn from a vein) with its LeadCare Testing Systems. Magellan’s primary product is the LeadCare II, a point-of-care (CLIA-waived) blood […]
Meridian Bioscience Engages Korn Ferry to Conduct CEO Search as John A. Kraeutler Announces Plans to Retire
CINCINNATI, May 10, 2017 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced it will commence a global search for a new Chief Executive Officer in conjunction with the planned retirement of John A. Kraeutler in accordance with the terms of his employment agreement. Mr. Kraeutler plans to continue to serve in the capacity of […]
Magellan Diagnostics (Meridian Bioscience, Inc., NASDAQ: VIVO) Launches National Education Initiative on Risks of Lead Exposure for Pregnant Women
Kickoff panel highlights common risks and what obstetricians can do to help protect their patients. CINCINNATI, May 09, 2017 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ:VIVO) announced today that Magellan Diagnostics Inc., a business unit of Meridian, has embarked on a major new initiative to increase awareness among obstetricians and pregnant women about the risks […]